Setting the Stage for Engineered B-Cell Therapies in Cancer and Autoimmune Disease
November 7th 2023David Rawlings, MD, the director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute, discussed findings from several preclinical studies that could help push engineered B-cell therapies towards clinical trials.
David Rawlings, MD, on the Potential of Engineered Treg Cells to Treat Autoimmune Diseases
October 24th 2023The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed preclinical research on overcoming limitations of Treg cells through genetic engineering.
David Rawlings, MD, on Research That Supports the Development of Engineered B-cell Therapies
October 17th 2023The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed findings from several preclinical studies that could help bring engineered B-cell therapies to clinical trials.